Title

從血清攝護腺特定抗原介於4-10 ng/ml病人中探討有效的攝護腺癌預測因子

Translated Titles

The assessment of useful parameters for detecting prostate cancer patients with total serum prostate-specific antigen between 4 and 10ng/ml

Authors

蔡銘順

Key Words

攝護腺癌 ; 血清攝護腺特定抗原 ; 血清攝護腺特定抗原密度 ; 游離態血清攝護腺特定抗原比率 ; prostate cancer ; prostate-specific antigen ; PSA density ; f/t PSA ratio

PublicationName

亞洲大學長期照護研究所在職專班學位論文

Volume or Term/Year and Month of Publication

2011年

Academic Degree Category

碩士

Advisor

藍守仁

Content Language

繁體中文

Chinese Abstract

背景與動機:隨著人口老化與飲食西化等因素影響,國人攝護腺癌的盛行率與死亡率逐年增加,自1980後期經直腸攝護腺超音波切片(Transrectal Ultrasonography Guilded Prostate Biopsy,TRUS Bx)已成為診斷攝護腺癌普遍使用的標準檢查流程,但隨之而來的檢查合併症與醫療花費亦不容忽視,本研究主要目的為透過血清攝護腺抗原(Prostate-Specific Antigen,PSA)所衍生出的數值,探討最有效的篩選工具,以降低病人接受不必要的攝護腺超音波切片檢查。 材料與方法:取自台中榮民總醫院2年內(自2009年2月至2011年1月)接受攝護腺切片檢查患者PSA值介於4-10ng/ml共計445檢次,分析血清攝護腺抗原密度(PSA Density,PSAD)、游離態血清攝護腺抗原比率(free to total PSA ratio,f/t PSA ratio)、肛門指診(Digital Rectal Examination,DRE)異常與否及經直腸攝護腺超音波(Transrectal Ultrasonography,TRUS)異常與否,等相關預測工具對於罹患攝護腺癌的預測。 結果:總樣本平均年齡為65.1歲±10.47(27-89歲),預測工具優劣結果依序為:f/t PSA ratio>PSAD>DRE>TRUS。統計分析比較,f/t PSA ratio≦0.17有最高的敏感度=82.9%,而其特異度=45.7%,為本研究最佳的單一攝護腺癌預測切點。若綜合二種以上預測工具以f/t PSA ratio≦0.17合併DRE可得最佳的敏感度=94.3%及可接受的特異度=35.0%。 結論:f/t PSA ratio是單一預測工具中可得最佳的癌症預測能力,我們應針對PSA為4-10ng/ml病人採集free PSA指數,並搭配肛門指診篩檢攝護腺癌。

English Abstract

Background:With the impact factor of aging population and the westernization of diet, the prevalence and mortality rate of people with prostate cancer increase annually. Since 1980 transrectal ultrasonography guilded prostate biopsy (TRUS Bx) has become a standard and common procedure for diagnosis of prostate cancer. However, the complications and medical costs accompanying inspection should not be ignored. The main purpose of this study is that how to use the parameter which are derived from the serum prostate-specific antigen (PSA) to explore the most effective screening tool to reduce unnecessary biopsies for prostate cancer patients. Materials and methods: Within 2 years (from February 2009 to January 2011) 445 inspection times are collected from the patients who accepted prostate biopsy and PSA values between 4-10ng/ml at Taichung Veterans General Hospital. By analyzing serum prostate-specific antigen density (PSAD)、free to total serum prostate-specific antigen ratio(f/t PSA ratio)、digital rectal examination(DRE)、transrectal ultrasonography (TRUS) for predicting prostate cancer. Results:The average age was 65.1 ± 10.47years old (range: 27-89 years). The prediction parameter from the best to the worst for prostate cancer was f/t PSA ratio> PSAD> DRE> TRUS. Statistic analysis and comparison, f/t PSA ratio≦0.17 was the best single cut-off point for prediction of prostate cancer with the best sensitivity=82.9% and specificity=45.7%. If combination of two or more prediction parameters, f/t PSA ratio≦0.17 combined with DRE, have the best sensitivity = 94.3% and acceptable specificity = 35.0%. Conclusion: f / t PSA ratio can get the best predictive ability for prostate cancer within single parameters. Free PSA of the serum should be collected for patients with PSA as 4-10ng/ml and combined DRE for screening prostate cancer.

Topic Category 醫藥衛生 > 社會醫學
健康學院 > 長期照護研究所在職專班
Reference
  1. 行政院衛生署國民健康局(2008)。衛生統計。2011年6月16日取自http://www.bhp.doh.gov.tw/BHPnet/Portal/StatisticsShow.aspx?No=200911300001
    連結:
  2. 陳卷書(2010)。利用血清PSA及其衍生數據預測再次攝護腺切片結果之研究。未出版之碩士論文,中山醫學大學醫學研究所,台中市。
    連結:
  3. 陳昶仲、吳錫金、張兆祥、陳汶吉、葉進仲、鄒頡龍等(2003)。十或十二針經直腸超音波攝護腺切片與傳統六針切片對攝護腺癌偵測的比較。中台灣醫學雜誌,8(2):102 -107。
    連結:
  4. 郭漢崇(2007)。泌尿學。花蓮:靜思文化。
    連結:
  5. 董宇平(2007)。前列腺腺癌的早期篩檢對醫療資源耗用影響之探討。未出版之碩士論文,高雄醫學大學醫學研究所,高雄市。
    連結:
  6. 鄭皓碩(2003)。從接受攝護腺切片病人的攝護腺特異抗原、肛門指診以及經直腸超音波研究前列腺切片之適應性。未出版之碩士論文,高雄醫學大學醫學研究所,高雄市。
    連結:
  7. Benson, M.C., Whang, I.S., Olsson, C.A., McMahon, D.J., Cooner, W.H. (1992).Use of prostate specific antigen density to enhance predictive value of intermediate levels of serum prostate specific antigen.The Journal of Urology,147,815-6.
    連結:
  8. Carter, H.B., Chan, D.W., Pearson, J.D., Guess, H.A., Waclawiw, S.Z., Walsh, P.C., et al.(1995) Prostate specific antigen variability in men without prostate cancer: The effect of sampling interval and number of repeat measurements on prostate specific antigen velocity.The Journal of Urology,45,591-6.
    連結:
  9. Catalona, W.J., Smith, D.S., Wolfert, R.L., Wang, T.J., Rittenhouse, H.G., Ratliff, T.L., et al.(1995)Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. The Journal of the American Medical Association,274,1214-20.
    連結:
  10. Catalona, W.J., Southwick, P.C., Slawin, K.M., Partin, A. W., Brawer, M.K., Flanigan, R.C.,(2000). Comparison of percent free PSA, PSA density,and age-specific PSA cutoffs for prostate cancer detection and staging.Adult Urology,56,255-260.
    連結:
  11. Chiang, I.N., Chang, S.J., Pu, Y.S., Huang, K.H., Yu, H.J., Huang, C.Y. (2007). Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: A retrospective study of 1875 cases in Taiwan. Journal Formosan Medical Association ,106(11),929-934.
    連結:
  12. Chiang, I.N., Chang S.J., Pu Y.S., Huang, K.H. , Yu, H.J., Huang, C.Y.(2009). Comparison of 6 and 12 core prostate biopsy in Taiwanese men: Impact of total prostate specific antigen, density and prostate volume on prostate cancer detection. Urologia Internationalis,82(3),270-275.
    連結:
  13. Djavan, B., Ravery, V., Zlotta, A., Dobronski, P., Dobrovits, M., Fakhari, M., et al.(2001). Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? The Journal of Urology,166,1679-1683.
    連結:
  14. Djavan, B., Zlotta, A.R., Byttebier, G., Shariat, S., Omar, M., Schulman, C.C., et al. (1998). Prostate specific antigen density of the transition zone for early detection of prostate cancer. The Journal of Urology,160,411-419.
    連結:
  15. Horninger, W., Pelzer, A.E., Bektic, J., Achleitner, R., Frauscher, F., Pallwein, L., et al.(2007). Complication rates of 7074 transrectal, ultrasound (TRUS) guided biopsies of the prostate results from the tyrol psa screening project.European Urology Supplements,6(2),121.
    連結:
  16. Kreutzer, N., Wolter, S., Haupt, G., Engelmann, U.(2002). Prospective study of anxiety, pain and complications due to prostate biopsy. European Urology Supplements,1,117.
    連結:
  17. Noldus, J.,Graefen, M.,Huland, E.,Busch, C.,Hammerer, P.,Huland, H.(1998). The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer. Journal Urology,159,2004-2008.
    連結:
  18. Partin, A.W., Brawer, M.K., Subong, E.N., Kelley, C.A., Cox, J.L., Bruzek, D.J., et al.(1998). Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Disease,1,197-203.
    連結:
  19. Tanaka1, N., Fujimoto1, K.,Chihara1, Y., Torimoto1, M., Hirao1, Y., Konishi, N.(2007). Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels. Prostate Cancer and Prostatic Diseases,10, 274-278.
    連結:
  20. 一、中文部分
  21. 行政院衛生署(2010)。統計公佈欄。2011年5月14日取自http://www.doh.gov.tw/CHT2006/DM/DM2_2_p02.aspx?class_no=440&now_fod_list_no=11468&level_no=1&doc_no=77184
  22. 行政院衛生署中央健康保險局(2011)。醫療費用支付標準查詢。2011年6月24日取自http://www.nhi.gov.tw/Query/query2.aspx?menu=18&menu_id=703
  23. 出口修宏(2010)。圖解前列腺Q&A。台北市:世茂。
  24. 美國國家疾病管制局(CDC,2011)衛生統計。2011年6月11日取自http://apps.nccd.cdc.gov/DCPC_INCA/DCPC_INCA.aspx
  25. 盧誌明、藍守仁(1997)。接收器運作指標曲線。台灣醫界,40(1),33-36。
  26. 攝護腺癌工作群編撰小組(2010)。攝護腺癌(前列腺)臨床診療指引。台北市:國家衛生研究院。
  27. 二、英文部分
  28. Catalona, W.J., Richie, J.P., Ahmann, F.R., Hudson, M.A., Scardino, P.T., Flanigan, R.C., et al.(2000) Extended field prostate biopsy enhances cancer detection.The Journal of Urology,55,453-456.
  29. Heidenreich, A., Aus, G., Bolla, M., Joniau, S., Matveev, V.B., Schmid, H.P., et al.(2008). EAU guidelines on prostate cancer.European Urology,53,68-80.
  30. Kirby, R.S., Kirby, M.G., Feneley, M.R., Mcnicholas, T., Mclean, A., Webb, J.A.W.(1994). Screening for carcinoma of the prostate:A GP based study. British Journal of Urology,74(1),64-71.
  31. Yang, C.R., Su, C.K., Chiu, K.Y., Ho, H.C., Ou, Y.C., Cheng, C.L., et al.(2005). Free/total PSA for prostate cancer detection: A prospective blind study. Anticancer Research,25,2439-2444.